辛伐他汀与替格瑞洛联用后对相互临床疗效的影响

摘要

OBJECTIVE:To evaluate the efficacy of simvastatin and ticagrelor either alone or in combination for acute coronary syndrome.METHODS: The patients with acute coronary syndrome were assigned to receive either simvastatin or ticagrelor alone or simvastatin plus ticagrelor.The uric acid, creatine kinase, low density lipoprotein-cholesterol, aspartate transaminase and the rate of platelet aggregation were measured and the efficacy of simvastatin and Ticagrelor either alone or in combination were compared.RESULTS:There were no significant differences between the combination group and simvastatin group or ticagrelor group in the anti-platelet aggregation rate and blood lipid levels (P>0.05).CONCLUSIONS: Studies have shown competitive inhibition of CYP3A4 between simvastatin and ticagrelor, resulting in certain influence on the pharmacokinetics, however, their clinical efficacy showed no significant change in the short term when used in combination.%目的：观察辛伐他汀与替格瑞洛联用后对相互的临床疗效是否存在影响。方法：将急性冠脉综合征患者随机分为单用辛伐他汀组、单用替格瑞洛组及两药联合应用组，测定各组患者血清尿酸、转氨酶、肌酸激酶、血小板聚集率、血脂水平等，比较在临床疗效上是否存在相互影响。结果：与单用辛伐他汀组、单用替格瑞洛组比较，联合用药组在抗血小板聚集率及血脂水平等方面的差异均无统计学意义（P＞0．05）。结论：尽管研究显示辛伐他汀、替格瑞洛存在CYP3A4的竞争性抑制，药动学方面有一定影响，但短期各自的临床疗效改变不显著。